echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Science Sub-journal key findings: New target for Alzheimer's disease - MSUT2

    Science Sub-journal key findings: New target for Alzheimer's disease - MSUT2

    • Last Update: 2020-06-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Like A-beta, Tau proteins accumulate and damage brain cells in the brains of AD patients, and the protein's association with AD stems from a finding more than 100 years ago that studies have revealed that Tau protein is the main component of a neuronal fibrous entanglement that characterizes AD pathologyAlthough it has since been widely accepted in the industry that Tau aggregation is only the result of the development of AD disease, some new developments have slowly confirmed that Tau aggregation may be a causative factor in ADimage source: Science Translational MedicineDecember 18, a new paper published in Science Translational Medicine, a team of scientists from the United States revealed that Tau, which targets abnormal abnormalities by suppressing a gene called MSUT2, has shown hopeAs long as the RNA binding protein PABPN1 (PolyA Binding Protein Nuclear 1) is not "exhausted," inhibiting MSUT2 may protect people from Alzheimer's disease, the study saidnormal, MSUT2 works closely with PABPN1 to regulate the biology of Tau in the brain"Our new study found that if MSUT2 was inhibited without affecting PABPN1, the effects of Tau pathology could be preventedBrian Kraemer, who led the study at the University of Washington School of Medicine, explainedMSUT2 was combined with poly(A) RNA tail and PABPN1 respectively (Photo: Science Translational Medicine)earlier, Kraemer and colleagues had used beautiful hidden bar nematodes to conduct researchThey found that although nematodes did not have complex cognitive functions, their movement sedits were affected by the accumulation of Tau proteins, and that the sut-2 gene for deworming could reverse Tau's "destructiveness."knowledge card: sut-2 is known as suppressor of tauopathy 2, and the gene encodes proteins that are conservatively homogenous in all species, from yeast to humansMSUT2 (also known as ZC3H14) is a mammalian homologous gene for nematode sut-2 genesin the latest study, scientists examining autopsy brain samples from Alzheimer's patientsMSUT2 enhances neuroinflammation, Tau pathology and neurodegeneration in the brains of mice (Photo: Science Translational Medicine)and found that patients with more severe conditions lacked both MSUT2 protein and their partner protein PABPN1Interestingly, mouse studies have shown that mice that lack MSUT2 but are normal for PABPN1 can strongly fight abnormal Tau and the brain degradation caused by it contrast this difference, Kraemer's team believes that the key to helping patients fight abnormal Tau aggregation may be to keep PABPN1 active while blocking MSUT2 inhibited MSUT2 in mice prevents Tau protein disease (Photo: Science Translational Medicine) by knocking out the MSUT2 gene in mice, they succeeded in preventing the formation of Tau protein entanglements that kill brain cells and reducing learning and memory problems Jeanna Wheeler, who was involved in the study , said the novelty of the study was the discovery of the role of the MSUT2 gene "From nematodes to mice to humans, we have confirmed that MSUT2 is associated with Tau toxicity Drugs targeted at MSUT2 could become a new treatment for Alzheimer's disease She said " In recent years, pharmaceutical companies have invested heavily in A-beta, but with little success I think the field needs to consider targeting both A-beta and Tau, because in Alzheimer's, these two proteins work together to kill neurons I hope that our findings will provide clues to follow-up research by other researchers or pharmaceutical companies that will ultimately lead to the goal of treating and even curing Alzheimer's disease Kraemer added small areas: Alzheimer's Journal: Science Translational Medicine Highlights: A team of scientists from the United States has found that by knocking out the MSUT2 gene in mice, it can successfully prevent the formation of Tau protein entanglements that kill brain cells and reduce learning and memory problems These results suggest that MSUT2 is expected to be a new target for the development of Alzheimer's drugs related papers: Science Translational Medicine (2019) Chris R Guthrie et al SUT-2 tha tau-induced neurotoxicity in Caenorhabditis elegance Human Molecular Genetics (2009) References: 1's Alzheimer's show promise in the protected brain from tau (Source: University of Washington)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.